CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases
Stopped early · Phase 3 · Has a placebo group
Conditions studied: Familial Hypoalphalipoproteinemia
In brief
The purpose of this study is to assess the impact of 29 intravenous infusions of CER-001 vs. placebo, given at weekly (9 infusions) and biweekly (20 infusions) intervals on carotid vessel wall area as measured by 3TMRI, when administered to patients with familial primary hypoalphalipoproteinemia with proven CVD and appropriate background lipid-lowering therapy.
Key facts
- Study ID
- NCT02697136
- Run by
- Cerenis Therapeutics, SA
- People needed
- 30
- Starts
- 2015-12-01
- Expected to finish
- 2018-12-21
- Last updated by the study team
- 2025-07-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Investigative Site — Salt Lake City, Utah, United States
- Investigative Site — La Louvière, Belgium
- Investigative Site — Vancouver, British Columbia, Canada
- Investigative Site — Halifax, Nova Scotia, Canada
- Investigative Site — London, Ontario, Canada
- Investigative Site — Chicoutimi, Quebec, Canada
- Investigative Site — Montreal, Quebec, Canada
- Investigative Site — Lille, France
- Investigative Site — Montpellier, France
- Investigative Site — Rouen, France
- Investigative Site — Toulouse, France
- Investigative Site — Jerusalem, Israel
- Investigative Site — Tel Aviv, Israel
- Investigative Site — Genoa, Italy
- Investigative Site — Milan, Italy
- Investigative Site — Pisa, Italy
- Investigative Site — Rome, Italy
- Investigative Site — Amsterdam, Netherlands
- Investigative Site — Utrecht, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.